Anti-malarial Medicines Market by Product and Geography - Forecast and Analysis 2021-2025

The anti-malarial medicines market share is expected to increase by USD 287.52 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 5%. This anti-malarial medicines market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. The anti-malarial medicines market report also offers information on several market vendors, including AstraZeneca Plc, Bayer AG, Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Mylan NV, Novartis AG, Pfizer Inc., Sanofi SA, and Sun Pharmaceutical Industries Ltd. among others. Furthermore, this report extensively covers anti-malarial medicines market segmentation by product (artemisinin compounds, quinolines and related compounds, and other compounds) and geography (Asia, ROW, Europe, and North America).

What will the Anti-malarial Medicines Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Anti-malarial Medicines Market Size for the Forecast Period and Other Important Statistics

Anti-malarial Medicines Market: Key Drivers, Trends, and Challenges

The strong funding to eradicate malaria is notably driving the anti-malarial medicines market growth, although factors such as drug-resistant pathogens may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the anti-malarial medicines industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Anti-malarial Medicines Market Driver

One of the key factors driving growth in the anti-malarial medicines market is the growing incidence of malaria. The growing incidence of malaria has increased the need for malaria rapid diagnostic devices, which can provide rapid test results and help in the diagnosis of the disease. The number of malaria cases is higher in Africa and Southeast Asian countries, owing to the lack of adequate healthcare infrastructure and less knowledge about parasitic infectious diseases. In 2018, the CDC reported that malaria was endemic in 91 countries and subtropics. According to WHO, there were almost 229 million cases globally of malaria in 2019. According to the OECD, about 2.3 million people across the world are at risk from malaria. Around 1 billion people in APAC, such as that in Papua New Guinea, Solomon Islands, Pakistan, India, Nepal, the Philippines, Indonesia, Myanmar, the Lao PDR, Cambodia, Thailand, China, Vietnam, Bangladesh, the Republic of Korea, and Malaysia, are at high risk of malaria. According to a report published by the CDC in 2019, around 219 million estimated cases of malaria were reported across the world. In addition, in the US, approximately 1,700 cases are diagnosed every year. To support and provide early diagnosis and treatment, CDC provides information related to malaria through its CDC Division of Parasitic Diseases and Malaria diagnostic website, which is available 24 hours a day.

Key Anti-malarial Medicines Market Trend

The development of prophylactic treatment is an antimalarial medicines market trend that is expected to have a positive impact in the coming years. The global anti-malarial medicines market is currently dominated by artemisinin compounds and by quinoline and its derivatives. These compounds are helpful only if the disease is effectively diagnosed, which itself is a challenge because of the complex life cycle of the disease. To overcome this, the market is inching toward developing a preventive mechanism against malaria in the form of various vaccines. All these years, the focus was on developing therapeutics for the treatment of malaria. However, the malaria parasites have a complex life span, and the current therapeutics do not offer lifelong protection. To overcome this challenge, many vaccines are being developed, some of which are expected to be marketed during the forecast period. For instance, RTS,S/AS01 by GlaxoSmithKline is an advanced malaria vaccine candidate. The development of such advanced treatment methods will fuel the growth of the global anti-malarial medicines market during the forecast period.

Key Anti-malarial Medicines Market Challenges

Drug-resistant pathogens are a major hindrance to the anti-malarial medicines market growth. Human malaria is caused mainly by four Plasmodium species, such as P. vivax, P. falciparum, P. ovale, and P. malariae. Some of these species are resistant to a single drug, while some are resistant to multiple drugs. This increases the probability and severity of the disease. Multidrug-resistant microbes are a major threat to human health currently. Such microbes change themselves to protect against the antimicrobial agent used, thereby developing resistance to the drug. This happens primarily due to the irrational use of drugs. The incorrect prescription of drugs by physicians or the incorrect dosing or course taken by patients, along with the increased use of similar drug ingredients in the agriculture and animal husbandry industries, leads to the development of such resistance. The commonly used anti-infective drugs thus become ineffective against the microbes, leading to the aggravation of the disease. This is reducing the acceptance of many anti-malarial medicines. In many countries, P. falciparum has become a chloroquine-resistant microbe, which leads to a worldwide increase in malaria-related mortality and morbidity rates. Thus, the drug resistance of microbes is expected to hinder the growth of the global anti-malarial medicines market during the forecast period.

This anti-malarial medicines market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Who are the Major Anti-malarial Medicines Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

• AstraZeneca Plc
• Bayer AG
• Cipla Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Mylan NV
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.

This statistical study of the anti-malarial medicines market encompasses successful business strategies deployed by the key vendors. The anti-malarial medicines market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The anti-malarial medicines market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Which are the Key Regions for Anti-malarial Medicines Market?

For more insights on the market share of various regions Request for a FREE sample now!

54% of the market's growth will originate from Asia during the forecast period. India, Indonesia, and Pakistan are the key markets for anti-malarial medicines in Asia. Market growth in Asia will be faster than the growth of the market in other regions.

The growing incidence of malaria will facilitate the anti-malarial medicines market growth in Asia over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Product Segments in the Anti-malarial Medicines Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The anti-malarial medicines market share growth by the artemisinin compounds segment will be significant during the forecast period. Artemisinin compounds are widely prescribed for the treatment of severe malaria caused by P. falciparum and for other forms of malaria caused by P. vivax. From the last decade, most of the malaria-related research and funding has been focused on the prevention, treatment, and control of P. falciparum. This indicates that the demand for artemisinin compounds will increase during the forecast period. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the anti-malarial medicines market size and actionable market insights on post COVID-19 impact on each segment.

Request for a FREE sample

What are the Key Data Covered in this Anti-malarial Medicines Market Report?

• CAGR of the market during the forecast period 2021-2025
• Detailed information on factors that will drive anti-malarial medicines market growth during the next five years
• Precise estimation of the anti-malarial medicines market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the anti-malarial medicines industry across Asia, ROW, Europe, and North America
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of anti-malarial medicines market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch